In Madhya Pradesh's Chhindwara district, the child death toll linked to contaminated cough syrup had risen to 14 by October 5, 2025. The number increased after a two-year-old girl died in Nagpur on the same day. The doctor who allegedly prescribed the syrup was arrested, and an FIR was registered against Dr. Soni. For exam preparation, the incident is not only a criminal-investigation update; it is a public-health case study on drug quality regulation, pharmacovigilance, and Centre-State coordination.

The syrup identified in reports was Coldrif cough syrup. Its sample was reported to contain diethylene glycol, pointing to drug adulteration and failure of quality checks. The Madhya Pradesh government banned the syrup and ordered stoppage of further sale, distribution, and seizure of available stock. The Central Drugs Standard Control Organisation is India's national drug regulatory authority, while State drug-control systems remain crucial because medicine safety depends on new drug approval, drug standards, imported-drug quality control, State coordination, and post-market surveillance.

Pharmacovigilance means detecting, assessing, understanding, and preventing adverse effects or other medicine-related problems. This incident can be linked with static GK on the Drugs and Cosmetics Act, 1940, drug adulteration, regulatory institutions, and public-health administration. In mains answers, it can be used as an example for accountability, relief to victims' families, quality-check capacity, and ensuring safe medicine supply even in smaller towns.